Latest Breaking News On - Amgen otezla - Page 7 : comparemela.com

Bristol-Myers Squibb Company (NYSE:BMY), Amgen Inc (NASDAQ:AMGN) - Bristol Myers Psoriasis Med Deucravacitinib Superior To Amgen s Otezla, New Data Shows

Bristol-Myers Squibb Company (NYSE:BMY), Amgen Inc (NASDAQ:AMGN) - Bristol Myers Psoriasis Med Deucravacitinib Superior To Amgen s Otezla, New Data Shows
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United statesAmgen otezlaAmerican academy of dermatology virtual meetingBristol myers squibb coDermatology virtual meetingஒன்றுபட்டது மாநிலங்களில்அமெரிக்கன் கலைக்கழகம் ஆஃப் தோல் நோய் மெய்நிகர் சந்தித்தல்பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் இணை

Unichem Laboratories share rises 8% on US FDA approval for Apremilast tablets

Unichem Laboratories share rises 8% on US FDA approval for Apremilast tablets The pharma share touched an intraday high of Rs 329.25, rising 7.74% on BSE BusinessToday.In | February 19, 2021 | Updated 17:12 IST Unichem Labs share stands higher than 5 day, 20 day, 50 day, 100 day and 200 day moving averages. Unichem Laboratories share price rose nearly 8 percent today after United States Food and Drug Administration s (US FDA) awarded approval for its Apremilast tablets. The stock has gained 6.9% in the last 4 days. The pharma share touched an intraday high of Rs 329.25, rising 7.74% on BSE. Unichem Labs share stands higher than 5 day, 20 day, 50 day, 100 day and 200 day moving averages. The share has gained 131.55% in one year and risen 22.66% since the beginning of this year. Later, the small cap stock closed 4.94% or Rs 15.10 higher at Rs 320.70.

United statesAmgen otezlaDrug administrationUnichem laboratoriesUnited states foodApremilast tabletsGupta equity research associateAngel brokingUnichem laboratories share priceUnichem laboratories share risesஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது மாநிலங்களில் உணவுகுப்தா பங்கு ஆராய்ச்சி இணைதேவதை தரகு

Unichem Labs spurts on USFDA nod for psoriasis drug

Unichem Laboratories surged 5.71% to Rs 323.05 after the company received United States Food and Drug Administration (USFDA) approval for apremilast tablets, 10 mg, 20 mg and 30 mg. The drug is a generic version of Amgen s Otezla (apremilast) tablets, 10 mg, 20 mg, and 30 mg. The drug is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. The scrip extended gains for third day. The stock has added 6.67% in three sessions from its recent closing low of Rs 302.85 recorded on 16 February 2021. In the past three months, the stock has added 36.73% while the benchmark Sensex has added 17.55% during the same period.

United statesAmgen otezlaDrug administrationUnichem laboratoriesUnited states foodCapital marketBranches of biologyMg carsMedroxyprogesterone acetateMagnesium in biologyPharmaceutical formulationsS ampp bse sensex indexUnited states food and drug administrationSevere plaqueஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது மாநிலங்களில் உணவு

Indices hover near day s low; breadth negative

The equity barometers were trading near the day s low in afternoon trade. The Nifty was hovering below 15,050 level. Rising COVID-19 case and negative global cues impacted domestic sentiment. PSU banks and auto shares corrected sharply. At 13:20 IST, the barometer index, the S&P BSE Sensex, dropped 216.25 points or 0.42% at 51,108.44. The Nifty 50 index lost 74.30 points or 0.49% at 15,044.65. Selling was broad based. The S&P BSE Mid-Cap index slipped 0.85%. The S&P BSE Small-Cap index fell 0.11%. Sellers outnumbered buyers. On the BSE, 1,400 shares rose and 1,444 shares fell. A total of 161 shares were unchanged. In Nifty 50 index, 12 stocks advanced while 38 stocks declined. Foreign portfolio investors (FPIs) bought shares worth Rs 903.07 crore, while domestic institutional investors (DIIs), were net sellers to the tune of Rs 1,217.34 crore in the Indian equity market on 18 February 2021, provisional data showed.

India generalUnited statesAndrew woodAurobindo pharmaAmgen otezlaBoris johnsonStatistics bureauUniversity of oxfordDrug administrationMinistry of healthIndusind bankUnited states food drug administrationLabor departmentSovereign international public finance ratingsTata motorsBajaj auto

Unichem Labs zooms 6% on USFDA approval for Apremilast tablets

Unichem Labs zooms 6% on USFDA approval for Apremilast tablets February 19, 2021 × The shares of Unichem Laboratories Limited gained six per cent on Friday after the company announced that it had received USFDA approval for its Apremilast Tablets. At 12:35, it was trading at ₹324 on the BSE, up ₹18.40 or 6.02 per cent. It hit an intra-day high of ₹329.25 and an intra-day low of ₹306. It opened at ₹306 as against the previous close of ₹305.6. On the NSE, it was trading at ₹323.55, up ₹18.30 or six per cent. The company on Friday announced that it has received ANDA approval for its Apremilast Tablets, 10 mg, 20 mg and 30 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Amgen’s Otezla (apremilast) Tablets, 10 mg, 20 mg, and 30 mg.

United statesAmgen otezlaDrug administrationUnichem laboratoriesUnichem laboratories limitedApremilast tabletsUnited states foodUnichem labsPlaque psoriaisisஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது மாநிலங்களில் உணவு